Loading page
Loading page
Loading substance route
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Propranolol carries lower risks for addiction or abuse compared to benzodiazepines. No significant psychological dependence or compulsive use patterns are documented.
Classic physical dependence does not develop; however, abrupt discontinuation in patients with cardiovascular conditions may cause serious rebound effects including exacerbation of angina or myocardial infarction. Gradual tapering is recommended.
Toxic plasma concentrations are associated with levels above 2,000 mg/L. Cardiac arrest may occur in overdose due to sudden ventricular arrhythmias or cardiogenic shock culminating in bradycardic pulseless electrical activity.
Overdose can cause severe bradycardia, hypotension, and potentially fatal cardiac arrest; chronic therapeutic use at typical doses has been associated with increased risk of type 2 diabetes in some populations.
May worsen symptoms of asthma and cause bronchospasm in patients with reactive airway disease; this risk is present even at therapeutic doses in susceptible individuals.
May mask signs and symptoms of hypoglycemia in diabetic patients, potentially allowing dangerous blood glucose levels to go unrecognized.
Seizures are associated with propranolol overdose, particularly hypoglycemic seizures. This risk is primarily an overdose concern rather than occurring at therapeutic doses.
Propranolol was developed by Scottish scientist James W. Black during the 1960s, representing a landmark achievement as the first beta-blocker to be effectively used in the treatment of coronary artery disease and hypertension. The compound was patented in 1962 and received approval for medical use…
Legally marketed as a prescription medication. Multiple brand name and generic formulations have been available since the early 1980s, including products under the Detensol and Apo-propranolol labels.
FDA approval was granted on November 13, 1967. Available as both brand name products (such as Hemangeol oral solution) and numerous generic formulations. Not classified as a controlled substance.
Legally marketed as a prescription medication. Available in both single-ingredient and combination formulations, such as DOCITEREN (propranolol combined with hydrochlorothiazide and triamterene), which has been marketed since 2006.
10 sources cited
